Aligos Therapeutics Inc. (ALGS)
NASDAQ: ALGSHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
ALGS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $33.16M
- EPS (TTM)
- -$7.33
- Dividend yield
- None
- 52-week range
- 3.98 – 13.69
- Day range
- 5.08 – 5.49
- Volume / Avg
- 37.36K / 88.98K
- Beta
- —
- Shares outstanding
- 5.44M
- Next earnings
- Nov 5, 2026
52-week range
ALGS stock today
On Oct 8, ALGS ended the session at $5.31, shedding $0.01 (0.19%), versus the S&P 500's 0.47% decline. Trading was light, with 37.36K shares changing hands, about 42% of the average daily volume. Shares are 61.2% below their 52-week high of $13.69, set on Dec 15, 2025 and 33.4% above the 52-week low of $3.98, near the bottom of the past year's range.
ALGS is down 43.0% year to date, underperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has lost 46.5%. Aligos Therapeutics has posted a net loss over the last twelve months (EPS of -$7.33), so its P/E ratio is not meaningful. Aligos Therapeutics's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Aligos Therapeutics
Company profileAligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Lawrence M. Blatt MBA, Ph.D.
- Headquarters
- South San Francisco, CA
- Employees
- 82
- IPO year
- 2020
- Website
- aligos.com
Analyst forecast
ForecastConsensus (8 analysts)
none
Avg. price target
$52.38+886.44%
- Strong buy 1
- Buy 7
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $-2.43
Aligos Therapeutics peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NNVCNanoViricides Inc. | 1.31 | -9.03% | $33.44M | vs ALGS |
| ATNMActinium Pharmaceuticals Inc. (Delaware) | 1.08 | +0.93% | $33.96M | vs ALGS |
| BCTXBriaCell Therapeutics Corp. | 3.92 | -2.00% | $34.10M | vs ALGS |
| GRDXGridAI Technologies Corp. | 4.80 | +16.50% | $34.23M | vs ALGS |
| CVMCel-Sci Corporation | 1.95 | -8.45% | $34.30M | vs ALGS |
| IBOImpact BioMedical Inc. | 4.11 | -8.26% | $35.11M | vs ALGS |
| NXTCNextCure Inc. | 6.78 | +3.35% | $31.03M | vs ALGS |
| QNCXQuince Therapeutics Inc. | 29.36 | +9.88% | $29.86M | vs ALGS |
Indexes, lists and sector
Appears in lists
Aligos Therapeutics stock FAQ
What is Aligos Therapeutics's stock price today?
ALGS last traded at $5.31 as of Oct 8, 4:00 PM EDT, down 0.19% on the day. Prices are delayed at least 15 minutes.
Does Aligos Therapeutics pay a dividend?
No. Aligos Therapeutics does not currently pay a regular cash dividend.
When is Aligos Therapeutics's next earnings date?
Aligos Therapeutics is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $-2.43.
Who is Aligos Therapeutics's CEO?
Dr. Lawrence M. Blatt MBA, Ph.D. is the chief executive officer of Aligos Therapeutics Inc., which has about 82 employees.
Has ALGS ever split its stock?
Yes. The most recent ALGS stock split was a 1-for-25 split on Aug 19, 2024.
What is the ALGS 52-week high?
The 52-week high for ALGS is $13.69 and the 52-week low is $3.98. The stock is currently 61.2% below its high.